The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.



Status:Archived
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:Any
Updated:7/1/2011

Use our guide to learn which trials are right for you!

Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.


The purpose of this study is to provide early access of TMC125 to HIV-1 infected patients
who have failed multiple antiretroviral (ARV) regimens. Information on safety and
tolerability aspects of TMC125 in combination with other ARVs in treatment-experienced HIV-1
patients with limited treatment options will be assessed. Available data regarding the
effectiveness of the drug will also be collected. To be eligible, patients should be
failing their current ARV regimen or be on a treatment interruption, should have previously
received 2 different protease inhibitor (PI) containing regimens and be at least 3-class
experienced (protease inhibitors [PI], nucleoside/tide reverse transcriptase inhibitors
[N[t]RTIs] and non-nucleoside reverse transcriptase inhibitors [NNRTIs]) or at least 2-class
experienced (PIs and N[t]RTIs) with primary NNRTI resistance. TMC125 will be administered in
combination with an investigator-selected background of additional ARVs from the list of
allowed medications.


This is an open label trial with primary objective to provide early access to TMC125 for
treatment-experienced HIV-1 infected patients who have failed multiple antiretroviral (ARV)
regimens and have limited treatment options with currently approved ARVs. The secondary
objective of this trial is to gather information on the safety and tolerability aspects of
TMC125 in combination with other ARVs. Available efficacy data will also be collected.
Patients should be at least 3-class experienced or 2-class experienced with primary
non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance. They should also have
previously received 2 different protease inhibitor-based regimens (low-dose ritonavir is not
counted as a protease inhibitor (PI) regimen), be on a treatment interruption or not be
virologically suppressed on their current regimen, and not be able to use currently approved
NNRTIs due to resistance (primary or acquired) and/or intolerance. Patients must also meet
all in- and exclusion criteria. TMC125 (200mg twice daily) will be provided once the patient
has been confirmed eligible for entry. Once treatment with TMC125 in combination with other
ARVs has been initiated, patients must be instructed to follow the recommended visit
schedule based on routine clinical care. Safety and tolerability of the entire
antiretroviral therapy (ART) regimen, including TMC125, should be monitored by the
investigator as per standard clinical practice. However, it is recommended that visits be
planned 4 and 12 weeks following initiation of TMC125 in combination with other ARVs and
every 12 weeks thereafter while on therapy during this trial. Adverse events (AEs) leading
to treatment interruption or discontinuation and all serious adverse events (SAEs), with the
exception of Acquired Immunodeficiency Syndrome (AIDS) defining illnesses (CDC class C)
unless fatal or considered to be related to TMC125, will be collected. Other adverse events
will be collected only if required as per local regulations. The background ARVs may be
changed at any time during the trial, at the discretion of the investigator due to the
development of resistance, intolerance, toxicity, etc. while continuing treatment with
TMC125 if in the investigator's assessment the patient still benefits from treatment with
TMC125. If changes in the background regimen are made, it is recommended that a follow-up
visit be planned 4 weeks after the change in therapy. Treatment with investigational
medication will be continued until virologic failure, treatment-limiting toxicity, subject
lost to follow-up, patient's withdrawal, pregnancy, discontinuation of TMC125 development or
when TMC125 has become commercially available in the patient's country. Patients will be
instructed to orally take two 100 mg tablets of TMC125 following a meal every 12 hours.
TMC125 (200 mg twice daily) must be used in combination with other antiretroviral drugs.
Treatment with investigational medication will continue until virologic failure,
treatment-limiting toxicity, patient lost to follow-up, withdrawal, pregnancy,
discontinuation of TMC125 development or when TMC125 becomes commercially available in the
patient's country.


We found this trial at
38
sites
Washington, District of Columbia
?
mi
from
Washington,
Click here to add this to my saved trials
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Albuquerque, New Mexico
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Atlanta, Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
Bettendorf, Iowa 52722
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
1351 Kimberly Rd
Bettendorf, Iowa 52722
(563) 355-7733
Hematology Oncology Associates of the Quad Cities
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Birmingham, Alabama
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Boston, Massachusetts
?
mi
from
Boston, MA
Click here to add this to my saved trials
Celebration, Florida
?
mi
from
Celebration, FL
Click here to add this to my saved trials
Centralia, Illinois
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Charleston, South Carolina
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlotte, North Carolina
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chevy Chase, Maryland 20815
?
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Denver, Colorado
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Ellsworth, Maine
?
mi
from
Ellsworth, ME
Click here to add this to my saved trials
Henderson, Nevada
?
mi
from
Henderson, NV
Click here to add this to my saved trials
Honolulu, Hawaii
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Jeffersonville, Indiana
?
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Lebanon, New Hampshire
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
?
mi
from
Lima, OH
Click here to add this to my saved trials
Louisville, Kentucky
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Medford, Oregon
?
mi
from
Medford, OR
Click here to add this to my saved trials
Metairie, Louisiana
?
mi
from
Metairie, LA
Click here to add this to my saved trials
Milwaukee, Wisconsin
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Morgantown, West Virginia
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
Mountlake Terrace, Washington
?
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
Nashville, Tennessee
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Newington, Connecticut
?
mi
from
Newington, CT
Click here to add this to my saved trials
Omaha, Nebraska
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Peoria, Arizona
?
mi
from
Peoria, AZ
Click here to add this to my saved trials
Philadelphia, Pennsylvania
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Providence, Rhode Island
?
mi
from
Providence, RI
Click here to add this to my saved trials
Richmond, Virginia
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials
St Louis, Missouri
?
mi
from
St Louis, MO
Click here to add this to my saved trials
West Orange, New Jersey
?
mi
from
West Orange, NJ
Click here to add this to my saved trials